ArticlePlant biotechnology journal2026
Convergent Evolution and De Novo Reconstitution of Apiin Biosynthesis.
Article in Plant biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phytochemicals fromFoods (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Apiin, an active flavonoid apioside, occurs in phylogenetically distant plants, such as parsley and chilli pepper (Capsicum annuum L.). Its sporadic distribution suggests the existence of convergent apiin biosynthesis; however, the molecular mechanisms underlying this convergence remain unclear. In this study, apiin biosynthesis in chilli pepper was comprehensively clarified. The structural genes involved in the biosynthesis of apigenin 7-O-glucoside, a precursor of apiin, were conserved using a homology-based approach. An apiin-biosynthetic apiosyltransferase (ApiGT), CaApiGT1, was identified from Capsicum annuum using comparative transcriptomic technology and in vitro enzymatic assays. Despite its strict specificity for the UDP-apiose donor, CaApiGT1 recognised multiple acceptors, including flavonoid 7-, 4'-and 3-O-glycosides. The sequence identity between CaApiGT1 and other apiin-biosynthetic ApiGTs was below 30%. CaApiGT1 (UGT79) and other apiin-biosynthetic ApiGTs (UGT94) belong to different UDP-dependent glycosyltransferase (UGT) families. These evidences collectively confirmed that CaApiGT1 is a novel ApiGT. Thus, convergent apiin biosynthesis was essentially caused by the convergent evolution of ApiGTs, rather than by distinct biosynthetic pathways between phylogenetically distant plants. Subsequently, CaApiGT1 was expressed in Escherichia coli to construct an engineered strain (EAA3PF) for apiin synthesis from apigenin. Additionally, an engineered Saccharomyces cerevisiae strain (YA3P) was developed for de novo apigenin synthesis. Co-cultivation of EAA3PF and YA3P reconstitutes the apiin biosynthetic pathway. This study provides new insight into the molecular convergence and de novo reconstitution of apiin biosynthesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.